Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care


1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974


Culakova, Eva, Ramya Thota, Marek S. Poniewierski, Nicole M. Kuderer, Adane F. Wogu, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.” Cancer Med 3, no. 2 (April 2014): 434–44.

Full Text

Arlen, M., J. Crawford, G. Coppa, O. Saric, J. Bandovic, A. Doubakovski, J. Sullivan, et al. “The cause and prevention of anastomotic recurrence following colectomy: An immunohistochemical approach for detecting transforming colonocytes.” Journal of Cancer 5, no. 9 (January 1, 2014): 784–89.

Full Text

Crawford, Jeffrey, Paul Swanson, Paul Schwarzenberger, Alan Sandler, Diane Prager, Kathy Zhang, Daniel J. Freeman, Carol W. Johnson, Kartik Krishnan, and David Johnson. “A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.” J Thorac Oncol 8, no. 12 (December 2013): 1510–18.

Full Text

Salama, Joseph K., Herbert Pang, Jeffrey A. Bogart, A William Blackstock, James J. Urbanic, Lydia Hogson, Jeffrey Crawford, and Everett E. Vokes. “Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.” Lung Cancer 82, no. 3 (December 2013): 436–40.

Full Text

Crawford, Jeffrey, Carla M. M. Prado, Michael L. Hancock, Mary A. Johnston, James T. Dalton, and Mitchell S. Steiner. “RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.” In Journal of Thoracic Oncology, 8:S1199–S1199. LIPPINCOTT WILLIAMS & WILKINS, 2013.


Ramalingam, S., J. Crawford, A. Chang, C. Manegold, R. Perez-Soler, J. -. Y. Douillard, N. Thatcher, et al. “Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).” Ann Oncol 24, no. 11 (November 2013): 2875–80.

Full Text

Meadows, Kellen L., Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, and Herbert I. Hurwitz. “Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.” Clinical Trials, November 2013.

Full Text

Pang, Herbert, Lydia Hodgson, Robert Kratzke, Jeffrey Crawford, Hedy Kindler, Everett Vokes, and Xiaofei Wang. “VALIDATION OF THE CALGB AND EORTC PROGNOSTIC MODELS FOR MESOTHELIOMA BASED ON MULTIPLE CALGB TRIALS (ALLIANCE).” Journal of Thoracic Oncology 8 (November 1, 2013): S934–35.


Crawford, Jeffrey, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, et al. “Myeloid growth factors.” J Natl Compr Canc Netw 11, no. 10 (October 1, 2013): 1266–90.

Full Text